Related Experiment Video
Updated: Aug 11, 2026

Murine Model of Allergen Induced Asthma
Published on: May 14, 2012
Preferential transmission and association of the -403 G --> A promoter RANTES polymorphism with atopic asthma
S A Al-Abdulhadi1, P J Helms, M Main
1Department of Child Health, University of Aberdeen, Royal Aberdeen Children Hospital, Aberdeen AB25 2ZG, Scotland, UK. saa@iahs.abdn.ac.uk
Abstract:
Asthma is a complex inherited disease. The study was undertaken to identify the association of RANTES promoter polymorphisms with atopy and asthma using family-based association tests (FBATs) and generation-specific case-control analyses. We identified 154 nuclear families (453 individuals) in whom we established RANTES promoter status using the RFLP-PCR method. Of the two known promoter polymorphisms -403G/A and -28C/G, only the former appeared with a clinically relevant frequency. A total of 61 families were eligible for assessment of transmission of the allele with asthma and atopy by the pedigree disequilibrium test (PDT). Overall, allele frequency for -403A was 38.3% and 84 of 89 (94.3%) alleles were transmitted with physician diagnosed asthma (PDA) (P=0.001). All 89 children with atopy received the mutant allele, which was more than expected following Mendelian Laws of transmission (P=0.0001). In 303 unrelated parents, significant associations of the mutant allele were for atopy with or without asthma (P=0.001). In 150 unrelated children, significant associations were for atopy alone (P=0.001) and asthma (P=0.001). No associations were found for bronchial hyper-responsiveness (BHR). The -403 G --> A is transmitted with atopy and atopic asthma, although its contribution appears to relate more to atopy than asthma and BHR.
Related Concept Videos
Epistasis
Exon Recombination
Exon shuffling follows “splice frame rules.” Each exon has three reading...
Single Nucleotide Polymorphisms-SNPs
Epistasis Analysis
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

